NEWS

NEWS 2020.12.11 Our R&D activity to develop a new T cell therapy for the novel coronavirus infection was introduced on Japanese TV program.

Professor Hiroshi Kawamoto, a director of Rebirthel, is recently conducting the collaborative r...

NEWS 2020.10.1 Rebirthel concluded the research license agreement with Otsuka Pharmaceutical.

Rebirthel Co., Ltd. (hereafter Rebirthel) concluded the research license agreement with Otsuka ...